CDRH Guardedly Optimistic About Brachytherapy For In-Stent Restenosis
This article was originally published in The Gray Sheet
Executive Summary
FDA Center for Devices and Radiological Health Director David Feigal praised the quality of evidence thus far demonstrating the safety and effectiveness of vascular brachytherapy in treating in-stent restenosis. At the same time, however, he cautioned that the agency would thoroughly review the data before making the therapy widely available.
You may also be interested in...
OEMs, FDA Still At Odds Over Premarket Requirements For Reprocessed SUDs
It appears unlikely that FDA will require all reprocessor submissions for single-use devices to support a "reusable" claim, despite opposing comments by Smith & Nephew and other original equipment manufacturers.
OEMs, FDA Still At Odds Over Premarket Requirements For Reprocessed SUDs
It appears unlikely that FDA will require all reprocessor submissions for single-use devices to support a "reusable" claim, despite opposing comments by Smith & Nephew and other original equipment manufacturers.
Guidant Begins ACS Multi-Link Radiation Stent European Clinicals
Guidant's initial European clinical study of the ACS Multi-Link radiation coronary stent system will enroll between 30 and 40 patients and collect data through six-months, the company says.